Use your antibodies-online credentials, if available.
抗Mouse (Murine) PSME3 抗体:
抗Rat (Rattus) PSME3 抗体:
抗Human PSME3 抗体:
the ubiquitin-independent REGgamma proteasome regulates energy homeostasis
Study demonstrated that Psme3/Psme4 double KO (dKO) male mice are completely infertile and showed the up-regulation of several proteins involved in oxidative stress response in dKO sperms. These results suggest the important role of PA28gamma and PA200 in male fertility.
Findings reveal a novel regulatory pathway in which the REGgamma-proteasome controls the steady-state level of GSK3beta protein.
PSME3 is a target gene of NF-kappaB during bacterial infections. PSME3 activates NF-kappaB by degrading KLF2.
REGgamma-mediated control of IkappaBvarepsilon contributes to NFkappaB activation and promotes bowel inflammation and associated tumour formation in response to chronic injury
REGgamma acts in skin tumorigenesis mediating MAPK/p38 activation of the Wnt/beta-catenin pathway.
In a p53-dominated cellular context, pro-apoptotic signaling might be overcome by PA28gamma-mediated caspase inhibition.
Data suggest levels of gene expression of both Psme3 (proteasome activator subunit 3) and Dusp3 (dual specificity phosphatase 3) are associated with susceptibility to Staphylococcus aureus infection/sepsis in humans and in mouse disease model.
PKA turnover by the REGgamma-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis.
REGgamma binds to SirT1, promotes its Ub-independent degradation, and inhibits its activity to deacetylate autophagy-related proteins, thereby inhibiting autophagy under normal conditions.
REGgamma-deficient mice develop premature aging phenotypes that are associated with abnormal accumulation of casein kinase (CK)1delta and p53. Antibody array analysis identified CK1delta as a direct target of REGgamma.
the regulation of REGgamma assembly and activity, suggesting a potential venue for the intervention of the ubiquitin-independent REGgamma proteasome activity.
PA28gamma acts as a co-repressor of HTLV-1 p30 to suppress virus replication and is required for the maintenance of viral latency.
PA28gamma stimulates MAFA degradation through a novel molecular mechanism that is distinct from that for the degradation of p21
Plasma cell differentiation to enable antibody secretion resulted in a transiently upregulated proteasome activator (PA) 28gamma, a component of the putative nuclear proteasome.
REGgamma regulates cellular distribution of p53 by facilitating its multiple monoubiquitylation and nuclear export.
REGgamma is present in many tissues and the highest expression is in the testis.
Loss of PA28g expression in 28-kDA proteasome activator gamma-deficient mice results in antigen-specific defects in the processing and presentation of MHC class I-restricted T cell epitopes.
REGgamma is not a viable therapeutic target in polyglutamine disease and that overall proteasome function is not impaired by trapped mutant polyglutamine in (Huntington's disease) R6/2 mice.
PA28gamma plays a crucial role in the development of liver pathology induced by HCV infection
Knockdown of REG-GAMMA (REGgamma) may inhibit the proliferation and migration, and promote the apoptosis of plasma cell myeloma RPMI-8226 cells possibly by downregulating NF-kappa-B (NF-kappaB) signal pathway.
data show that PIP30 deeply affects PA28gamma interactions with cellular proteins, including the 20S proteasome, demonstrating that it is an important regulator of PA28gamma in cells and thus a new player in the control of the multiple functions of the proteasome within the nucleus.
High expression of REGg seemed positively correlated with T-stage and lymph node metastasis in papillary thyroid carcinoma tissues.
This study demonstrates that REGgamma is a central molecule in the development of melanoma by regulating Wnt/beta-catenin pathway.
that Proteasome activator subunit 3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and influencing the tumor immune microenvironment in breast cancer
PSME3 plays an oncogenic role in pancreatic cancer by inhibiting c-Myc degradation to promote glycolysis.
Study demonstrated that the gene therapy with proteasome activator, PA28gamma can improve ubiquitin-proteasome system function as well as behavioral abnormalities in Huntington's disease model mice
Surrogate Prognostic Biomarkers in OSCC: The Paradigm of PA28gamma Overexpression.
PA28gamma in OSCC tumor tissues were significantly high expression than those in normal tissues.
Results show molecular cloning of a novel transcript variant encoding a truncated form of PA28G likely involved in cell cycle regulation and apoptosis.
Our results suggest that the high expression of REGgamma might predict metastasis and poor prognosis in breast cancer.
Increased PA28gamma sera levels were prognostic of disease activity in rheumatoid arthritis.
Data suggest levels of gene expression of both PSME3 (proteasome activator subunit 3) and DUSP3 (dual specificity phosphatase 3) are associated with susceptibility to Staphylococcus aureus infection/sepsis in humans and in mouse disease model.
Examination of EC and normal endometrium specimens confirmed the oncogenic role of REGgamma, in that REGgamma was more highly overexpressed in p53-positive specimens than in p53-negative specimens.
PA28 gamma and p53 form a negative feedback loop that maintains the balance of p53 and PA28gamma in the cells.
Our data indicate that miR-7-5p has a critical function through blocking REGgamma in breast cancer cells.
REGgamma expression is positively correlated with ERalpha status and poor clinical prognosis in ERalpha positive breast cancer patients
The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits\; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The immunoproteasome contains an alternate regulator, referred to as the 11S regulator or PA28, that replaces the 19S regulator. Three subunits (alpha, beta and gamma) of the 11S regulator have been identified. This gene encodes the gamma subunit of the 11S regulator. Six gamma subunits combine to form a homohexameric ring. Alternate splicing results in multiple transcript variants.
11S regulator complex subunit gamma
, activator of multicatalytic protease subunit 3
, ki nuclear autoantigen
, proteaseome (prosome, macropain) 28 subunit, 3
, proteasome activator 28 subunit gamma
, proteasome activator complex subunit 3
, 11S regulator complex gamma subunit
, Ki antigen
, Ki nuclear autoantigen
, PA28 gamma variant 5
, proteasome activator 28-gamma
, proteasome activator subunit 3